Cresco assisted an investor consortium in the structuring, negotiation and closing of its EUR 37m Series A investment round in Camel-IDS.
The consortium was led by V-Bio Ventures(Belgium) and Gimv(Belgium), and joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland).
Camel-IDS is a VUB spin-off and develops novel radiopharmaceuticals, using camelid single domain antibody fragments (sdAb) labelled with radioisotopes. These innovative radiopharmaceuticals will primarily be used in treatment of breast cancer.
More information on the transaction can be found here.
For any further information or questions, please contact David Dessers.